Arrowhead Pharmaceuticals (ARWR) EBITDA Margin (2010 - 2026)
Arrowhead Pharmaceuticals' (ARWR) quarterly EBITDA Margin came in at 191.57% in Q1 2026, down 26181.0% YoY from N/an in Q1 2025, and down 1339.47% on a QoQ basis from 15.46% in Q4 2025.
Arrowhead Pharmaceuticals (ARWR) EBITDA Margin (2010 - 2026) Analysis & Trends
Arrowhead Pharmaceuticals (ARWR) has 17 years of EBITDA Margin data on file, last reported at 191.57% in Q1 2026.
- Quarterly EBITDA Margin fell 26181.0% year-over-year to 191.57% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 35.67% (down 1393.0% YoY) and the FY2025 annual result came in at 11.86%, up 1693892.0% from the prior year.
- EBITDA Margin eased to 191.57% in Q1 2026, from 15.46% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 70.24% in Q1 2025 to a low of 6456.48% in Q4 2024.
- A 5-year average of 914.72% and a median of 208.26% in 2022 frame the typical range for EBITDA Margin.
- Annual changes were most pronounced in 2023 — EBITDA Margin tumbled 377789 bps — and 2025, when it soared 647194 bps.
- Tracing ARWR's EBITDA Margin over 5 years: stood at 67.36% in 2022, then tumbled by 5608 bps to 3845.25% in 2023, then slumped by 68 bps to 6456.48% in 2024, then jumped by 100 bps to 15.46% in 2025, then plunged by 1339 bps to 191.57% in 2026.
- The last three EBITDA Margin figures came in at 191.57% (Q1 2026), 15.46% (Q4 2025), and 17.2% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,569,866.34% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Arrowhead Pharmaceuticals | 12.23 Bn | 10.63 Bn | - | -226.03% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -226.03% |
| Mar 31, 2026 | -191.57% |
| Dec 31, 2025 | 15.46% |
| Sep 30, 2025 | 17.20% |
| Jun 30, 2025 | -596.21% |
| Mar 31, 2025 | 70.24% |
| Dec 31, 2024 | -6,456.48% |
| Dec 31, 2023 | -3,845.25% |
| Sep 30, 2023 | -672.98% |
| Jun 30, 2023 | -648.99% |
| Mar 31, 2023 | 32.93% |
| Dec 31, 2022 | -67.36% |
| Sep 30, 2022 | -265.49% |
| Jun 30, 2022 | -224.94% |
| Mar 31, 2022 | 27.37% |
| Dec 31, 2021 | -230.77% |
| Sep 30, 2021 | -169.48% |
| Jun 30, 2021 | -69.44% |
| Mar 31, 2021 | -86.04% |
| Dec 31, 2020 | -112.91% |